Centrifugation and Depth Filtration Process Development
Rapid and Data-Rich Study in Downstream mAb Purification
Program Overview
- Overcome challenges with limited time and development materials
- Upstream feed variability (viable cell count (VCC) viability, wet cell weight, etc.) during development
- Overcome limited cell culture batches
In this webinar, we explore how to conduct a rapid and data-rich study in downstream monoclonal antibody (mAb) purification.
mAbs are a class of biopharmaceuticals that have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Downstream purification is a critical step in the production of mAbs, and it involves several techniques, including centrifugation and depth filtration.
Centrifugation is a widely used technique in the biopharmaceutical industry for separating and concentrating biomolecules. In downstream mAb purification, it is used to remove cell debris and other impurities from the product stream. On the other hand, depth filtration is a highly efficient technique for removing contaminants from the product stream based on size exclusion and adsorption.
In this presentation, Amelia Burke discusses how GSK developed and optimized centrifugation and depth filtration processes for mAb purification.
About the Presenter
Amelia Burke, M.S.
Technology Manager, GSK
